ArticleEvidence-based complementary and alternative medicine : eCAM2019
Protective Effects of Angong Niuhuang Pill on Early Atherosclerosis in ApoE
Article in Evidence-based complementary and alternative medicine : eCAM, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Genome-wide identification and characterization of the AP2/ERF gene family in Cinnamomum camphora.BMC genomics · 2025Article
- Unpredictable Chemical Diversity of Essential Oils inMolecules (Basel, Switzerland) · 2024Article
- Article
- Bioactive Peptides from Lupin (Journal of agricultural and food chemistry · 2022Article
- Mineral medicine: from traditional drugs to multifunctional delivery systems.Chinese medicine · 2022Review
- Exploring Active Compounds and Mechanisms of Angong Niuhuang Wan on Ischemic Stroke Based on Network Pharmacology and Molecular Docking.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Source Apportionment and Health Risk Assessment of Heavy Metals in Endemic Tree Species in Southern China: A Case Study ofFrontiers in plant science · 2022Article
- Atheroprotective Effects and Mechanisms of Postmarketing Chinese Patent Formulas in Atherosclerosis Models: A Systematic Review.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Genome-Wide Identification and Functional Characterization of the Trans-Isopentenyl Diphosphate Synthases Gene Family inFrontiers in plant science · 2021Article
- Article
- Principles and treatment strategies for the use of Chinese herbal medicine in patients at different stages of coronavirus infection.American journal of cancer research · 2020Review
- Anti-Atherosclerosis Effect of Angong Niuhuang PillFrontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) is the primary cause of cardiocerebrovascular disease, and inflammation is responsible for the initiation of its pathogenesis. Therefore, targeting inflammatory pathways to prevent AS progression is an ideal strategy. Angong Niuhuang pill (ANP) is a well-known traditional Chinese medicine and has been widely used for thousands of years to treat central nervous system and cardiovascular diseases. In this study, we investigated the role of ANP in reducing inflammation during early AS, using a high-fat diet-induced ApoE
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.